SG10201808496VA - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy - Google Patents
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapyInfo
- Publication number
- SG10201808496VA SG10201808496VA SG10201808496VA SG10201808496VA SG10201808496VA SG 10201808496V A SG10201808496V A SG 10201808496VA SG 10201808496V A SG10201808496V A SG 10201808496VA SG 10201808496V A SG10201808496V A SG 10201808496VA SG 10201808496V A SG10201808496V A SG 10201808496VA
- Authority
- SG
- Singapore
- Prior art keywords
- hexahydroimidazo
- methylbenzyl
- pyrimidin
- benzyl
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin- 5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1); or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially. Fig. 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779828P | 2013-03-13 | 2013-03-13 | |
| US201361904718P | 2013-11-15 | 2013-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201808496VA true SG10201808496VA (en) | 2018-10-30 |
Family
ID=51527915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507247WA SG11201507247WA (en) | 2013-03-13 | 2014-03-13 | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| SG10201808496VA SG10201808496VA (en) | 2013-03-13 | 2014-03-13 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507247WA SG11201507247WA (en) | 2013-03-13 | 2014-03-13 | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9265765B2 (en) |
| EP (2) | EP3572083A1 (en) |
| JP (3) | JP6446025B2 (en) |
| KR (2) | KR102438135B1 (en) |
| CN (1) | CN105530937A (en) |
| AU (3) | AU2014244117B2 (en) |
| BR (1) | BR112015023256A2 (en) |
| CA (2) | CA3204801A1 (en) |
| CY (1) | CY1121735T1 (en) |
| DK (1) | DK2968294T3 (en) |
| EA (1) | EA037937B1 (en) |
| ES (1) | ES2734568T3 (en) |
| HK (1) | HK1217653A1 (en) |
| HR (1) | HRP20191181T1 (en) |
| HU (1) | HUE044238T2 (en) |
| IL (2) | IL241452B (en) |
| LT (1) | LT2968294T (en) |
| ME (1) | ME03470B (en) |
| MX (2) | MX2015012636A (en) |
| NZ (2) | NZ751509A (en) |
| PL (1) | PL2968294T3 (en) |
| PT (1) | PT2968294T (en) |
| RS (1) | RS59013B1 (en) |
| SG (2) | SG11201507247WA (en) |
| SI (1) | SI2968294T1 (en) |
| WO (1) | WO2014160130A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6132833B2 (en) | 2011-04-29 | 2017-05-24 | ザ ペン ステイト リサーチ ファンデーション | Small molecule TRAIL gene induction of normal and tumor cells as anticancer therapy |
| PL2968294T3 (en) | 2013-03-13 | 2019-10-31 | Oncoceutics Inc | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| EP3305812B1 (en) | 2013-03-14 | 2020-06-17 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| NZ747418A (en) | 2014-03-12 | 2023-05-26 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| EP3662910A1 (en) | 2014-03-31 | 2020-06-10 | The Scripps Research Institute | Pharmacophore for trail induction |
| MX2021001096A (en) * | 2015-01-30 | 2023-01-17 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy. |
| CN104860948B (en) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | Imidazopyrimidine ketone compounds and its preparation method and application |
| SG10202101740QA (en) * | 2015-08-17 | 2021-04-29 | Kura Oncology Inc | Methods of treating cancer patients with farnesyl transferase inhibitors |
| KR20170037260A (en) | 2015-09-25 | 2017-04-04 | 현대자동차주식회사 | Battery Management System for vehicle and controlling method thereof |
| BR112018015590A2 (en) | 2016-01-29 | 2019-10-01 | Oncoceutics Inc | g protein coupled receptor (gpcr) modulation by imipridones |
| CN114191428A (en) | 2016-03-02 | 2022-03-18 | 卫材研究发展管理有限公司 | Eribulin-based antibody-drug conjugates and methods of use |
| KR20170110520A (en) * | 2016-03-23 | 2017-10-11 | 고려대학교 산학협력단 | Composition comprising mTOR inhibitor and N-acetylcysteine for inhibiting hepatic fibrosis |
| AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| US11229703B2 (en) * | 2016-04-06 | 2022-01-25 | Noxopharm Limited | Radiotherapy improvements |
| JP2019527738A (en) * | 2016-08-12 | 2019-10-03 | ナンジン ゲイター メディテック カンパニー, リミテッドNanjing Gator Meditech Company, Ltd. | Protein kinase regulator |
| JP2019534290A (en) | 2016-11-03 | 2019-11-28 | クラ オンコロジー， インコーポレイテッド | Farnesyltransferase inhibitors for use in methods of treating cancer |
| WO2018129080A1 (en) * | 2017-01-04 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Target genes in myc-driven neoplasia |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| IT201800004082A1 (en) * | 2018-03-29 | 2019-09-29 | Berlin Chemie Ag | ANTI-CANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY |
| US20200046703A1 (en) * | 2018-08-09 | 2020-02-13 | Asymmetric Therapeutics, Llc | Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| WO2020147842A1 (en) * | 2019-01-18 | 2020-07-23 | 南京明德新药研发有限公司 | Use of pyridopyrimidine compounds in preparation of drug for treating nasopharyngeal carcinoma |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| WO2021104454A1 (en) * | 2019-11-28 | 2021-06-03 | 应世生物科技(南京)有限公司 | Use of bi853520 in cancer treatment |
| AU2021247415A1 (en) | 2020-03-30 | 2022-09-29 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
| CN117599041B (en) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | Medical application of dehydroequol and derivative thereof as novel radioprotectant and cytoprotectant |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (en) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo(1,2-a)pyrido(4,3-d)pyrimidines - withcns activity |
| US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| HUE038768T2 (en) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| US20110287001A1 (en) * | 2008-09-22 | 2011-11-24 | Tetralogic Pharmaceuticals | Method of treatment |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| DE102010014426A1 (en) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
| JP6132833B2 (en) * | 2011-04-29 | 2017-05-24 | ザ ペン ステイト リサーチ ファンデーション | Small molecule TRAIL gene induction of normal and tumor cells as anticancer therapy |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| PL2968294T3 (en) | 2013-03-13 | 2019-10-31 | Oncoceutics Inc | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
| EP3662910A1 (en) | 2014-03-31 | 2020-06-10 | The Scripps Research Institute | Pharmacophore for trail induction |
-
2014
- 2014-03-13 PL PL14775569T patent/PL2968294T3/en unknown
- 2014-03-13 SG SG11201507247WA patent/SG11201507247WA/en unknown
- 2014-03-13 US US14/208,657 patent/US9265765B2/en active Active
- 2014-03-13 EP EP19171477.3A patent/EP3572083A1/en not_active Withdrawn
- 2014-03-13 HU HUE14775569 patent/HUE044238T2/en unknown
- 2014-03-13 ME MEP-2019-197A patent/ME03470B/en unknown
- 2014-03-13 KR KR1020157028393A patent/KR102438135B1/en active IP Right Grant
- 2014-03-13 JP JP2016501988A patent/JP6446025B2/en active Active
- 2014-03-13 WO PCT/US2014/025885 patent/WO2014160130A1/en active Application Filing
- 2014-03-13 EA EA201591715A patent/EA037937B1/en unknown
- 2014-03-13 KR KR1020227029471A patent/KR20220123335A/en not_active Application Discontinuation
- 2014-03-13 CA CA3204801A patent/CA3204801A1/en active Pending
- 2014-03-13 DK DK14775569.8T patent/DK2968294T3/en active
- 2014-03-13 PT PT14775569T patent/PT2968294T/en unknown
- 2014-03-13 SI SI201431257T patent/SI2968294T1/en unknown
- 2014-03-13 CA CA2905037A patent/CA2905037C/en active Active
- 2014-03-13 SG SG10201808496VA patent/SG10201808496VA/en unknown
- 2014-03-13 LT LTEP14775569.8T patent/LT2968294T/en unknown
- 2014-03-13 BR BR112015023256A patent/BR112015023256A2/en not_active Application Discontinuation
- 2014-03-13 EP EP14775569.8A patent/EP2968294B1/en active Active
- 2014-03-13 CN CN201480022856.7A patent/CN105530937A/en active Pending
- 2014-03-13 NZ NZ751509A patent/NZ751509A/en active IP Right Revival
- 2014-03-13 ES ES14775569T patent/ES2734568T3/en active Active
- 2014-03-13 MX MX2015012636A patent/MX2015012636A/en active IP Right Grant
- 2014-03-13 NZ NZ711948A patent/NZ711948A/en unknown
- 2014-03-13 AU AU2014244117A patent/AU2014244117B2/en not_active Ceased
- 2014-03-13 RS RS20190874A patent/RS59013B1/en unknown
-
2015
- 2015-09-10 IL IL241452A patent/IL241452B/en active IP Right Grant
- 2015-09-11 MX MX2019013643A patent/MX2019013643A/en unknown
-
2016
- 2016-05-19 HK HK16105766.3A patent/HK1217653A1/en unknown
-
2018
- 2018-06-22 JP JP2018119005A patent/JP2018184411A/en active Pending
-
2019
- 2019-03-19 AU AU2019201896A patent/AU2019201896A1/en not_active Abandoned
- 2019-07-01 CY CY20191100687T patent/CY1121735T1/en unknown
- 2019-07-01 HR HRP20191181TT patent/HRP20191181T1/en unknown
-
2020
- 2020-06-23 IL IL275623A patent/IL275623A/en unknown
- 2020-07-01 JP JP2020114024A patent/JP2020172510A/en active Pending
- 2020-09-14 AU AU2020233606A patent/AU2020233606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201808496VA (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pytido[3.4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy | |
| MX2022001966A (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]p yrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use. | |
| EA201991877A2 (en) | 7-BENZyl-4- (2-methylbenzyl) -2,4,6,7,8,9-hexahydroimidazo [1,2-A] pyrido [3,4-E] pyrimidine-5 (1H) -OH, its SALTS AND METHODS OF APPLICATION | |
| MX2023000782A (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy. | |
| EA201590870A1 (en) | AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use | |
| PH12018502134A1 (en) | Methods of treating pediatric cancers | |
| MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| EA201691385A1 (en) | Combined Cancer Therapy | |
| MX2015013155A (en) | Tetrandrine family pharmaceutical formulations and method. | |
| WO2014186388A3 (en) | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |